Period October – December 2021
• Net sales: 84,042 (0) TSEK.
• Other operating revenues: 1,098 (3,171) TSEK.
• Profit from financial items: 57,448 (-10,964) TSEK.
• Earnings per share: 2.90 (-1.22) SEK.

Period January – December 2021
• Net sales: 84,042 (0) TSEK.
• Other operating revenues: 7,478 (12,029) TSEK.
• Profit from financial items: 20,965 (-29,551) TSEK.
• Earnings per share: 1.21 (-3.31) SEK.
• Liquidity as per the end of the reporting period: 136,744 (48,895) TSEK.
• Equity ratio as per the end of the reporting period: 95 (89)%.
• The board proposes that no dividend will be paid for the 2021 financial year.

October-December 2021
• CombiGene and Spark Therapeutics enter exclusive, global licensing agreement for gene therapy candidate CG01. The agreement with Spark has a potential value of USD 328.5 million excluding royalties, with USD 8.5 million upon signing and up to USD 50 million at preclinical and clinical milestones.
• CombiGene’s Horizon 2020 project successfully completed with a final payment of approximately EUR 500,000, which means that CombiGene has received the full grant of EUR 3.36 million.
• CombiGene and Spark Therapeutics communicate plan to expand the clinical development program beyond the EU, to also include the U.S. This also expands the preclinical program.

Events after the end of the period
• GMP production of CG01 made available for preclinical studies planned to enable First in Human study.
• CombiGene signs agreement with University of Michigan to evaluate the leading gene therapy candidate within the lipodystrophy project CGT2.

Link to the report

Contacts

Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63
jan.nilsson@combigene.com

Bert Junno, Chairman of the board
Phone: +46 (0)707 77 22 09
bert.junno@combigene.com

www.combigene.com
CombiGene AB (publ) Agavägen 52A, SE-181 55 Lidingö, Sweden
info@combigene.com

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
 
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
 
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)8 52 80 03 99, info@fnca.se.

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282.
CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714

Attachments

CombiGene Q4 2021 ENG

© Modular Finance, source Nordic Press Releases